• 1
    Hauner H. Insulin resistance and the metabolic syndrome-a challenge of the new millennium. Eur J Clin Nutr 2002; 56 (Suppl. 1): S259.
  • 2
    Mottillo S, Filion KB, Genest J et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 111332.
  • 3
    Mikhailidis DP, Elisaf M, Rizzo M et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 53371.
  • 4
    Mikhailidis DP, Elisaf M, Rizzo M et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 5312.
  • 5
    Gazi IF, Milionis HJ, Filippatos TD et al. Hypertriglyceridaemic waist phenotype criteria and prevalent metabolic triad in women. Diabetes Metab Res Rev 2008; 24: 22330.
  • 6
    Gazi IF, Filippatos TD, Tsimihodimos V et al. The hypertriglyceridemic waist phenotype is a predictor of elevated levels of small, dense LDL cholesterol. Lipids 2006; 41: 64754.
  • 7
    Rizzo M, Pernice V, Frasheri A et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf) 2009; 70: 8705.
  • 8
    Kontush A, Chapman MJ. Antiatherogenic small, dense HDL--guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3: 14453.
  • 9
    Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008; 23: 3708.
  • 10
    Asztalos BF, Cupples LA, Demissie S et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24: 21817.
  • 11
    Lagos KG, Filippatos TD, Tsimihodimos V et al. Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 2009; 44: 916.
  • 12
    Agouridis AP, Tsimihodimos V, Filippatos TD, Tselepis AD, Elisaf MS. High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011; 46: 5218.
  • 13
    Agouridis AP, Tsimihodimos V, Filippatos TD et al. The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother 2011; 12: 260511.
  • 14
    Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 16405.
  • 15
    Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 22739.
  • 16
    Kostapanos MS, Milionis HJ, Lagos KG, Rizos CB, Tselepis AD, Elisaf MS. Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. Eur J Pharmacol 2008; 590 (1–3): 32732.
  • 17
    Kostapanos MS, Milionis HJ, Filippatos TD et al. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 2009; 14: 513.
  • 18
    Grundy SM, Becker D, Clark LT et al. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143421.
  • 19
    Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP. Editorial: Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? Curr Vasc Pharmacol 2012; 10: 1737.
  • 20
    Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006; 55: 88591.
  • 21
    Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005; 149: 3345.
  • 22
    Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 838.
  • 23
    Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005; 81: 35866.
  • 24
    Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 122536.
  • 25
    Chapman MJ, Ginsberg HN, Amarenco P et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 134561.
  • 26
    Kotani K, Asahara-Satoh N, Kato Y et al. Remnant-like particle cholesterol and serum amyloid a-low-density lipoprotein levels in obese subjects with metabolic syndrome. J Clin Lipidol 2011; 5: 395400.
  • 27
    Kostapanos MS, Milionis HJ, Filippatos TD et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 2007; 29: 140314.
  • 28
    Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 10669.
  • 29
    Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010; 8: 61231.
  • 30
    Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract 2009; 63: 130813.
  • 31
    Hiukka A, Leinonen E, Jauhiainen M et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007; 50: 206775.
  • 32
    Saougos VG, Tambaki AP, Kalogirou M et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27: 223643.
  • 33
    Filippatos TD, Gazi IF, Liberopoulos EN et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193: 42837.
  • 34
    Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 208893.
  • 35
    Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19: 47284.
  • 36
    Lemieux I, Salomon H, Despres JP. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients. Ann Med 2003; 35: 4428.
  • 37
    Melenovsky V, Malik J, Wichterle D et al. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002; 144: E6.
  • 38
    Krysiak R, Stachura-Kulach A, Okopien B. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. Pharmacol Rep 2010; 62: 12030.
  • 39
    Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21: 19972006.
  • 40
    Lemieux I, Laperriere L, Dzavik V, Tremblay G, Bourgeois J, Despres JP. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients. Atherosclerosis 2002; 162: 36371.
  • 41
    Winkler K, Weltzien P, Friedrich I et al. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL. Exp Clin Endocrinol Diabetes 2004; 112: 2417.
  • 42
    May HT, Anderson JL, Pearson RR et al. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 2008; 101: 4869.
  • 43
    Abeywardena MY, Patten GS. Role of omega3 Longchain Polyunsaturated Fatty Acids in Reducing Cardio-Metabolic Risk Factors. Endocr Metab Immune Disord Drug Targets 2011; 11: 23246.
  • 44
    Maki KC, Lawless AL, Kelley KM et al. Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol 2011; 57: 48994.
  • 45
    Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol 2011; 5: 48392.
  • 46
    Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008; 102: 42933.
  • 47
    Krysiak R, Gdula-Dymek A, Okopien B. Hemostatic effects of bezafibrate and omega-3 fatty acids in isolated hypertriglyceridemic patients. Pharmacol Rep 2011; 63: 76371.
  • 48
    Nigam A, Frasure-Smith N, Lesperance F, Julien P. Relationship between n-3 and n-6 plasma fatty acid levels and insulin resistance in coronary patients with and without metabolic syndrome. Nutr Metab Cardiovasc Dis 2009; 19: 26470.
  • 49
    Akinkuolie AO, Ngwa JS, Meigs JB, Djousse L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr 2011; 30: 7027.
  • 50
    Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH. Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome. J Clin Endocrinol Metab 2008; 93: 4307.
  • 51
    Filippatos TD, Liberopoulos EN, Kostapanos M et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008; 10: 47683.
  • 52
    Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 2008; 49: 26417.
  • 53
    Knopp RH, Walden CE, Warnick GR, Albers JJ, Ginsberg J, McGinnis BM. Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E. Am J Med 1987; 83: 7584.
  • 54
    Tribble DL, Farnier M, Macdonell G et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008; 57: 796801.
  • 55
    Berneis K, Rizzo M, Stettler C et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin Pharmacother 2008; 9: 3439.
  • 56
    Ohira M, Miyashita Y, Ebisuno M et al. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2007; 78: 3441.